Novo Nordisk CEO defends economics of Wegovy pill as lower prices weigh on sales; shares fall
AI disclosure
Summary
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.